

CADTH Reference List

Minimally Invasive Treatments for People With Benign Prostatic Hyperplasia

February 2023

Authors: Elijah Herington, Sharon Bailey

Cite As: Minimally Invasive Treatments for People With Benign Prostatic Hyperplasia. (CADTH reference list). Ottawa: CADTH; 2023 Feb.

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up to date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to requests@cadth.ca

Key Messages

- One primary qualitative study was identified that explored the perspectives on, expectations of, or experiences with accessing and undergoing a minimally invasive treatment for benign prostatic hyperplasia.
- No primary qualitative studies were identified that explored the perspectives on, expectations of, or experiences with minimally invasive treatment for benign prostatic hyperplasia of sexual partners to people living with benign prostatic hyperplasia.

Research Question

What evidence is available that explores the perspectives, expectations, and experiences of people with benign prostatic hyperplasia, or their sexual partners, regarding accessing or engaging with minimally invasive treatments for benign prostatic hyperplasia?

Methods

Literature Search Methods

A limited literature search was conducted by an information specialist on key resources including MEDLINE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Scopus. The search strategy comprised both controlled vocabulary, such as the National Library of Medicine’s MeSH (Medical Subject Headings) and keywords. The main search concepts were benign prostatic hyperplasia and minimally invasive treatments related to benign prostatic hyperplasia. Search filters were applied to limit retrieval to qualitative studies. Where possible, retrieval was limited to humans. The search was completed on February 6, 2023, and limited to English-language documents published since January 1, 2018. Internet links were provided, where available.

Selection Criteria

One reviewer screened literature search results (titles and abstracts) and selected publications according to the inclusion criteria presented in [Table 1](#). Full texts of study publications were not reviewed.

Table 1: Selection Criteria

Criteria	Description
Sample	Adults aged ≥ 18 with benign prostatic hyperplasia for whom conservative management has failed, or their sexual partners
Phenomenon of interest	Minimally invasive treatment for benign prostatic hyperplasia (e.g., Rezum, iTind, UroLift)
Design	Any qualitative design

Criteria	Description
Evaluation	Perspectives on, expectations of, and experiences with accessing and undergoing minimally invasive treatment for benign prostatic hyperplasia
Research type	Primary qualitative studies

Results

One primary qualitative study was identified that explored the perspectives on, expectations of, or experiences with accessing and undergoing a minimally invasive treatment for benign prostatic hyperplasia.¹ No primary qualitative studies were identified that explored the perspectives on, expectations of, or experiences with minimally invasive treatment for benign prostatic hyperplasia of sexual partners to people living with benign prostatic hyperplasia.

Additional references of potential interest that did not meet the inclusion criteria are provided in [Appendix 1](#).

References

Primary Qualitative Studies

1. Holm A, Lindgren H, Blackberg M, et al. Patients' perspective on prostatic artery embolization: A qualitative study. *SAGE Open Med.* 2021;9:20503121211000908. [PubMed](#)

Appendix 1: References of Potential Interest

Health Technology Assessments with Patient Engagement Report

2. Ontario Health (Quality). Prostatic artery embolization for benign prostatic hyperplasia: A health technology assessment. *Ont Health Technol Assess Ser.* 2021;21(6):1-139. [PubMed](#)

Surveys and Patient Preference Studies

3. Huffman PJ, Yin E, Cohen AJ. Evaluating patient preferences in benign prostatic hyperplasia treatment using conjoint analysis. *Urology.* 2022;164:211-217. [PubMed](#)
4. Bouhadana D, Nguyen DD, Zorn KC, Elterman DS, Bhojani N. Patient perspectives on benign prostatic hyperplasia surgery: A focus on sexual health. *J Sex Med.* 2020;17(10):2108-2112. [PubMed](#)
5. Tutrone RF, Schiff W. Early patient experience following treatment with the UroLift prostatic urethral lift and Rezum steam injection. *Can J Urol.* 2020;27(3):10213-10219. [PubMed](#)

Qualitative Study Exploring BPH Treatment Decision Making Broadly

6. Husted M, Gray D, Golding SE, Hindley R. Reaching a tipping point: A qualitative exploration of quality of life and treatment decision-making in people living with benign prostatic hyperplasia. *Qual Health Res.* 2022;32(13):1979-1992. [PubMed](#)